elements
-live
Search elements, keywords, and sectors
🔎
Elements
Subjects
Papers
Communities
Lab
Pricing
Log in
Sign up
Home
/
Subjects
/
Metastatic Urothelial Carcinoma
← Back to subjects
Current data, viewed at
Yearly
resolution.
Personal members see monthly resolution →
Keyword
keyword
Metastatic Urothelial Carcinoma
RIS
0.003
(Research Intensity Score)
Papers
149
Top papers
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer
2024 · 972 citations
Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma
2023 · 479 citations
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines
2025 · 191 citations
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Carcinoma: 2023 Update
2023 · 510 citations
Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma
2021 · 1181 citations
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
2020 · 1524 citations
Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial
2025 · 89 citations
Enfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer
2023 · 185 citations
TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors
2021 · 542 citations
Newest papers
Neoadjuvant and adjuvant enfortumab vedotin (EV) plus pembrolizumab (pembro) for participants with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin: Randomized, open-label, phase 3 KEYNOTE-B15 study.
2026 · 12 citations
Liver metastases in advanced urothelial carcinoma (ARON-2): do pembrolizumab and avelumab make a difference in a poor-prognosis scenario?
2026 · 1 citations
PROGNOSTIC VALUE OF THE HALP SCORE IN METASTATIC UROTHELIAL CARCINOMA TREATED WITH FIRST-LINE PLATINUM-BASED CHEMOTHERAPY
2026
C-reactive protein at pembrolizumab initiation and its trajectory from first-line chemotherapy as prognostic markers in metastatic urothelial carcinoma (YUSHIMA study)
2026
Integrative Genomic Analysis Reveals Molecular and Clinical Disparities between Bladder and Upper Tract Urothelial Carcinoma in K-MASTER Program
2026
Conversion to Pathological Complete Response by Enfortumab Vedotin in Metastatic Sarcomatoid Urothelial Carcinoma With Nectin‐4 Expression: A Case Report
2026
Antibody Drug Conjugates in Urothelial Carcinoma: Current Evidence and Practice Considerations
2026
Real-World Patterns of First-Line Treatment Selection After the Introduction of Enfortumab Vedotin Plus Pembrolizumab for Advanced Urothelial Carcinoma
2026
Cost-effectiveness of disitamab vedotin plus toripalimab in HER2-expressing advanced urothelial carcinoma in China
2026
Browse all papers →
Metastatic Urothelial Carcinoma's history
Research intensity over time
Yearly
Personal members see monthly resolution →
Data temporarily unavailable — please try again shortly.
Close ✕
Metastatic Urothelial Carcinoma's papers
Ordered by current research-activity contribution.
Loading…
Close ✕
Read full text ↗
Share
Share on X
Share on Facebook
Share on LinkedIn
Copy link